Company news
ImmunityBio, Inc. news in 2022
ImmunityBio, Inc.'s news releases, calls and decks from 2022, newest first.
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
December 11, 2022
ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference
November 16, 2022
NEJM Evidence Publishes Results for ImmunityBio’s QUILT 3.032 Registrational Trial of IL-15 Superagonist N-803 Plus BCG in Patients with Bladder Cancer
November 9, 2022
ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ
July 27, 2022
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
June 5, 2022
ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ
May 22, 2022
ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022
ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer
April 24, 2022
ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ
March 31, 2022
Memory Cytokine-Enhanced Natural Killer Cells Show Promising Results in Leukemia Patients; Data Support ImmunityBio’s Scaled m-ceNK Clinical Program
March 1, 2022
ImmunityBio Completes Acquisition of Athenex’s Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility
February 14, 2022
ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer
February 13, 2022
ImmunityBio Announces Promising Clinical Study Results for ‘Kick and Kill’ HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy
January 30, 2022
ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival
January 17, 2022
ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness
January 11, 2022
ImmunityBio Awarded Seminal Patent on Natural Killer Cells
January 3, 2022
Amyris and ImmunityBio complete joint venture for next generation COVID-19 RNA vaccine
January 2, 2022
Decks in 2022
- Investor Presentation (November 2022)
Investor deck · 30 slides · Nov 15, 2022
- Jefferies Healthcare Conference 2022
Conference · 32 slides · Jun 10, 2022